A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.
Melanoma News
BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the treatment arm.
What to Know About Adjuvant Immunotherapy for Stage II/III Melanoma
Adjuvant immunotherapy with anti-PD-1 agents improves relapse-free survival in patients with stage II or III melanoma. But does everyone need treatment?
Shorter Anti-PD1 Therapy Duration Not Associated With Worse Survival in Melanoma
Among patients with resected metastatic melanoma stages III and IV, a shorter treatment duration with adjuvant anti-PD1 antibodies is not associated with worse outcomes, according to study results published in the Journal of the European Academy of Dermatology and Venereology.